We are live on
!
Find out more
CC
ClearArc Capital Portfolio holdings
AUM
$257M
1-Year Est. Return
33.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.52%
1 Year Est. Return
+33.81%
3 Year Est. Return
+63.41%
5 Year Est. Return
+95.17%
10 Year Est. Return
–
AUM
$434M
AUM Growth
+$29.2M
(+7.2%)
Cap. Flow
+$11.3M
Cap. Flow
% of AUM
2.61%
Top 10 Holdings %
Top 10 Hldgs %
16.68%
Holding
407
New
26
Increased
249
Reduced
113
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLB Ltd
SLB
|
+$2.08M |
| 2 |
SVC
Service Properties Trust
SVC
|
+$1.9M |
| 3 |
PPL
PPL Corp
PPL
|
+$1.79M |
| 4 |
Camden Property Trust
CPT
|
+$1.59M |
| 5 |
DRE
Duke Realty Corp.
DRE
|
+$1.53M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$1.55M |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.1M |
| 3 |
BP
BP
|
+$798K |
| 4 |
Xerox
XRX
|
+$774K |
| 5 |
AstraZeneca
AZN
|
+$716K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 15.83% |
| 2 | Technology | 14.13% |
| 3 | Healthcare | 12.38% |
| 4 | Energy | 11.6% |
| 5 | Industrials | 10.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Parker-Hannifin
PH
$135B
| $378K | 0.09% |
3,008
-266
| -8% | -$33.2K |
|
|
RAI
252
DELISTED
Reynolds American Inc
RAI
| $378K | 0.09% |
12,528
+226
| +2% | +$6.48K |
|
|
MJN
253
DELISTED
Mead Johnson Nutrition Company
MJN
| $378K | 0.09% |
4,059
+58
| +1% | +$5.07K |
|
254
Estee Lauder
EL
$32B
| $377K | 0.09% |
5,076
-667
| -12% | -$49K |
|
255
Southwest Airlines
LUV
$23B
| $374K | 0.09% |
13,929
+40
| +0.3% | +$1.01K |
|
256
Vornado Realty Trust
VNO
$7.38B
| $374K | 0.09% |
4,784
+83
| +2% | +$6.3K |
|
257
Omnicom Group
OMC
$23.4B
| $371K | 0.09% |
5,212
+86
| +2% | +$5.99K |
|
258
Perrigo
PRGO
$1.78B
| $367K | 0.08% |
2,516
+18
| +0.7% | +$2.55K |
|
259
Broadcom
AVGO
$2.04T
| $366K | 0.08% |
+50,740
| New | +$341K |
|
|
FITB
260
Fifth Third Bancorp
FITB
$51.8B
| $365K | 0.08% |
17,115
+251
| +1% | +$5.32K |
|
261
Boston Properties
BXP
$11.1B
| $364K | 0.08% |
3,079
+38
| +1% | +$4.49K |
|
262
Agilent Technologies
A
$41.2B
| $360K | 0.08% |
8,771
+56
| +0.6% | +$2.25K |
|
263
AutoZone
AZO
$51.1B
| $357K | 0.08% |
665
-4
| -0.6% | -$2.12K |
|
264
Sherwin-Williams
SHW
$89.8B
| $354K | 0.08% |
5,139
+81
| +2% | +$5.41K |
|
265
Rockwell Automation
ROK
$49B
| $350K | 0.08% |
2,798
-426
| -13% | -$52.5K |
|
266
Dollar General
DG
$27.9B
| $349K | 0.08% |
6,091
+270
| +5% | +$15.4K |
|
267
Zimmer Biomet
ZBH
$18.4B
| $349K | 0.08% |
3,462
-464
| -12% | -$45.3K |
|
268
AvalonBay Communities
AVB
$26.8B
| $348K | 0.08% |
2,449
+40
| +2% | +$5.53K |
|
269
KBR
KBR
$4.8B
| $344K | 0.08% |
14,409
+634
| +5% | +$15.9K |
|
270
Wynn Resorts
WYNN
$10.6B
| $341K | 0.08% |
1,644
-10
| -0.6% | -$2.07K |
|
271
Boston Scientific
BSX
$71.5B
| $340K | 0.08% |
26,600
+378
| +1% | +$4.92K |
|
272
Consolidated Edison
ED
$39.9B
| $340K | 0.08% |
5,880
+91
| +2% | +$5.08K |
|
|
K
273
DELISTED
Kellanova
K
| $338K | 0.08% |
5,478
+54
| +1% | +$3.38K |
|
274
Roper Technologies
ROP
$39.8B
| $338K | 0.08% |
2,313
+328
| +17% | +$45.8K |
|
275
Host Hotels & Resorts
HST
$16B
| $335K | 0.08% |
15,224
+245
| +2% | +$5.27K |
|
Similar funds
BO
GCA
QCM
AEPI
AC
LA
JFM
SHA
ClearArc Capital's Q2 2014 Portfolio in Review
As of Q2 2014, ClearArc Capital held 407 positions worth $434M, up 7.2% from $405M the previous quarter. Its ten largest holdings account for 17% of the portfolio.
ClearArc Capital's Q2 2014 filing shows 26 new, 249 increased, 113 reduced and 16 closed positions. Its largest new stake was Service Properties Trust: 12,988 shares worth $1.96M. The largest sale was Pfizer, an estimated $1.55M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
- ClearArc Capital's largest Q2 2014 buy was Service Properties Trust: 12,988 shares worth $1.96M.
- ClearArc Capital added most to SLB Ltd in Q2 2014, an estimated $2.08M increase.
- ClearArc Capital's biggest Q2 2014 reduction was Pfizer, cutting an estimated $1.55M.
- ClearArc Capital fully exited AstraZeneca in Q2 2014, selling an estimated $716K.
- ClearArc Capital's ten largest holdings make up 17% of its $434M portfolio in Q2 2014.
- ClearArc Capital opened 26 new positions and closed 16 in Q2 2014.
- ClearArc Capital's portfolio value rose 7.2% quarter-over-quarter to $434M.
Based on ClearArc Capital's 13F filing for Q2 2014, filed 14 Aug 2014.